ATB Therapeutics is pioneering a new era in targeted therapies by developing next-generation Antibody-Drug Conjugates (ADCs) to transform cancer treatment. By combining cutting-edge biotechnology with a strong commitment to improving patient outcomes, they aim to deliver safer, more effective, and highly selective treatments that address unmet medical needs.

Their proprietary atbodies™ platform allows them to design and produce unique biological molecules that merge the specificity of antibodies with potent payload delivery, achieving unprecedented precision in targeting cancer cells while sparing healthy tissues. With innovation at their core and a world-class team driving progress, ATB Therapeutics is turning therapeutic possibilities into tangible solutions for patients around the globe.